TriangleRelacorilant (NCT05726292)
Relacorilant trial for Prostate Cancer (NCT05726292). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with surgically removable, high-risk prostate adenocarcinoma without distant spread. Prior hormone therapy for prostate cancer is excluded.
The idea: all participants receive enzalutamide and hormone suppression before prostate removal. Random assignment adds relacorilant or placebo. Relacorilant blocks glucocorticoid receptors, while the other treatments reduce androgen signaling that supports prostate cancer. Researchers examine removed tissue for complete response or minimal remaining disease after 24 weeks of treatment.
This phase 2 study plans 90 patients. Russell Szmulewitz leads at the University of Chicago; three US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.